Trials / Conditions / Sporadic Inclusion Body Myositis

Sporadic Inclusion Body Myositis

9 registered clinical trials studyying Sporadic Inclusion Body Myositis.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Sporadic Inclusion Body Myositis Natural History Study NCT05046821	University of California, Irvine	—
Completed	Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis NCT04421677	University of Kansas Medical Center	Phase 1
Withdrawn	Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis NCT03710941	Regeneron Pharmaceuticals	Phase 2
Unknown	Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study NCT02735447	La-ser Europe Limited	—
Completed	An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic I NCT02573467	Novartis Pharmaceuticals	Phase 3
Completed	Blood-flow Restricted Exercise in Inclusion Body Myositis NCT02317094	University of Southern Denmark	N/A
Completed	Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM P NCT01925209	Novartis Pharmaceuticals	Phase 2 / Phase 3
Completed	Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis NCT01519349	Nationwide Children's Hospital	Phase 1
Completed	Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis NCT01423110	Novartis Pharmaceuticals	Phase 2